



authors declare that no
competing interests exist.
Funding: See page 18
Received: 14 November 2019
Accepted: 05 June 2020
Published: 23 June 2020
Reviewing editor: Matthew G
Vander Heiden, Massachusetts
Institute of Technology, United
States
Copyright Contat et al. This
article is distributed under the
terms of the Creative Commons
Attribution License, which
permits unrestricted use and
redistribution provided that the
original author and source are
credited.
Combined deletion of Glut1 and Glut3
impairs lung adenocarcinoma growth
Caroline Contat1,2, Pierre-Benoit Ancey1,2, Nadine Zangger1,2,3, Silvia Sabatino1,2,
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Abstract Glucose utilization increases in tumors, a metabolic process that is observed clinically
by 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET). However, is increased
glucose uptake important for tumor cells, and which transporters are implicated in vivo? In a
genetically-engineered mouse model of lung adenocarcinoma, we show that the deletion of only
one highly expressed glucose transporter, Glut1 or Glut3, in cancer cells does not impair tumor
growth, whereas their combined loss diminishes tumor development. 18F-FDG-PET analyses of
tumors demonstrate that Glut1 and Glut3 loss decreases glucose uptake, which is mainly
dependent on Glut1. Using 13C-glucose tracing with correlated nanoscale secondary ion mass
spectrometry (NanoSIMS) and electron microscopy, we also report the presence of lamellar body-
like organelles in tumor cells accumulating glucose-derived biomass, depending partially on Glut1.
Our results demonstrate the requirement for two glucose transporters in lung adenocarcinoma, the
dual blockade of which could reach therapeutic responses not achieved by individual targeting.
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Introduction
Glucose transporters are the first and rate-limiting step for cellular glucose utilization, a process
often exacerbated in tumor cells that enables their growth and proliferation (Ancey et al., 2018;
Lunt and Vander Heiden, 2011). Although inhibiting glucose metabolism in lung tumors could
become an efficient treatment strategy (Hensley et al., 2016; Patra et al., 2013; Xie et al., 2014),
whether and which glucose transporter(s) should be targeted remains unclear because of their possi-
ble functional redundancy. Additionally, in solid cancers, tumor cell growth can be fueled by
nutrients other than glucose, or by using transporter-independent metabolic processes including
autophagy and macropinocytosis (Commisso et al., 2013; Karsli-Uzunbas et al., 2014;
Romero et al., 2017; Son et al., 2013).
In this study, we exploited the KrasLSL-G12D/WT; Trp53Flox/Flox (KP) mouse model of lung adenocar-
cinoma to explore the importance of glucose transporters, expressed by tumor cells, in disease
development. By glucose tracing and ultrastructural analyses, we identified the presence of lamellar
body-like organelles in tumor cells, which are the primary site of glucose-derived biomass accumula-
tion, occurring partly in a Glut1-dependent manner. We show that the deletion of Glut1 or Glut3 is
not sufficient to decrease tumor progression, which is only affected significantly upon combined
Glut1 and Glut3 loss.
Results and discussion
To interrogate the importance of particular glucose transporters in the most frequent subtype of
lung cancer, lung adenocarcinoma (LUAD), we used The Cancer Genome Atlas specific for LUAD
(TCGA-LUAD) to compare gene expression within the facilitated glucose transporter (GLUT, gene
name SLC2A) family. SLC2A1 (GLUT1) followed by SLC2A3 (GLUT3) were the most expressed mem-
bers, (Figure 1a) and high SLC2A1 expression was correlated with poor overall survival (Figure 1—
figure supplement 1a). From a human tissue microarray comprising 18 cases of stage IB-IIB LUAD
and 18 cases of stage IA-IIB lung squamous cell carcinoma (LUSC), GLUT1 protein was detected in
all tumors. Specifically, it showed intermediate and strong GLUT1 expression in 44% (8/18) and 56%
(10/18) of the LUAD lesions, respectively (Figure 1b). In LUSCs, GLUT1 exhibited strong staining in
all samples (Figure 1b), confirming previous results obtained from squamous cell carcinomas of lung
and other tissues (Goodwin et al., 2017; Hsieh et al., 2019). To obtain more information about
SLC2A1 expression in LUAD, we applied a non-negative matrix factorization of TCGA-LUAD sam-
ples, which generated four distinct clusters (NMF1-4, Figure 1—figure supplement 1b). SLC2A1
and SLC2A3 were the most expressed in NMF4, which contains the highest percentage of the TP53
mutation (Figure 1c). In the immunocompetent KrasLSL-G12D/WT; Trp53Flox/Flox (KP) mouse model
where tumors consist of pure LUADs all harboring Trp53 gene deletion, RNA sequencing analyses of
bulk tumor samples revealed a predominance of NMF4-like lesions (Figure 1—figure supplement
1c). Glut1 protein levels in tumor cells gradually increased along tumor progression, with the major-
ity of advanced grade lesions being positive with intermediate or strong Glut1 staining (Figure 1—
figure supplement 2a). In normal lung, Glut1 was only weakly expressed or undetectable in the
alveolar compartment that comprises alveolar type-1 and 2 (AT1, AT2) cells, endothelial cells and
alveolar macrophages (Figure 1—figure supplement 2b), AT2 cells being considered as the princi-
pal tumor cell-of-origin in this model (Desai et al., 2014; Sutherland et al., 2014; Xu et al., 2012).
In contrast, Glut1 was strongly expressed in the bronchiolar epithelial compartment that contains
Club cells, another cell type permissive to tumor initiation (Sutherland et al., 2014; Figure 1—fig-
ure supplement 2b). To determine the contribution of Glut1 for tumor development, we crossed KP
mice to Slc2a1Flox/Flox (G1) animals (Young et al., 2011), and initiated tumors in the resulting KPG1
mice and control KP mice by intratracheal lentiviral-Cre instillation (Lenti.PGK-Cre, Figure 1—figure
supplement 2c–d). During tumor progression, we detected slightly but not significantly reduced
changes in tumor growth rates monitored by X-rays micro-computed tomography (mCT) (Figure 1d).
At sacrifice, although no significant difference was observed in the weight or in the number of
lesions (Figure 1e–f), a significant reduction of high grade tumors (grades 4 and 5) was determined
upon Glut1 loss in KP lesions (Figure 1g). Because there was no significant increase in KPG1 mouse
survival (Figure 1h), these data together fail to reveal a clear impact of Glut1 deletion in the tumor
epithelial cells on disease progression.
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Figure 1. Glut1 deletion does not impact disease progression in KrasLSL-G12D/WT; Trp53Flox/Flox mice. (a) Gene expression level (RSEM) of glucose
transporters in TCGA-LUAD samples (n = 511). (b) Immunohistochemistry (IHC) from a next-generation tissue microarray of human LUAD and LUSC
showing score 1 (intermediate) or score 2 (strong) GLUT1 staining. The number of cases per score and histology are indicated. Scale bars: 100 mm. (c)
Expression level (log2 normalized) of SLC2A1 and SLC2A3 in the 4 NMF LUAD subtypes. Percent of TP53 mutation in each subtype is indicated. (d)
Graph with mean ± s.e.m. shows the fold changes of KP and KPG1 tumor volumes (n = 32 and 26, respectively) monitored during 28 days by mCT,
starting at 16 weeks and 6 days post-tumor initiation with tumor volumes set to 1. ns: not significant by Mann-Whitney test. (e) Dot plot with mean ± s.d.
shows KP and KPG1 tumor weights (n = 17 and 21) at sacrifice 29 weeks post-tumor initiation. ns: not significant by Mann-Whitney test. (f) Dot plot with
mean ± s.d. shows the average number of KP and KPG1 tumors per mouse (n = 7 and 6 mice). ns: not significant by Mann-Whitney test. (g) Percent of
KP (n = 128) and KPG1 (n = 102) lesions classified by tumor grades, either detailed from alveolar hyperplasia (AH) to grade 5 or discriminated between
alveolar hyperplasia and adenomas, and adenocarcinomas. Alveolar hyperplasia and adenomas include the AH and the tumor grades 1, 2, and 3.
Adenocarcinomas contain the tumor grades 4 and 5. **: p < 0.01. Fisher test was applied when comparing AH, grade 1, grade 2, grade 3, grade 4, and
grade 5. Chi-square for trend was applied when comparing alveolar hyperplasia and adenomas, and adenocarcinomas. (h) Kaplan-Meier survival
analysis of KP (n = 8) and KPG1 (n = 6) mice. ns: not significant by Log-rank test.
The online version of this article includes the following source data and figure supplement(s) for figure 1:
Figure 1 continued on next page
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To detect if there are measurable changes in glucose utilization secondary to Glut1 deletion in
vivo, we decided to monitor glucose-derived biomass accumulation in tumors with ultrastructural
resolution. Specifically, we performed 13C-glucose injections followed by nanoscale secondary ion
mass spectrometry (NanoSIMS) imaging (Hoppe et al., 2013) correlated with electron microscopy
(EM) (Figure 2a). Intense 13C enrichments inside tumors revealed a compartmentalized intracellular
accumulation of glucose-derived biomass, which can be attributed to a specific organelle of tumor
cells visualized by the superposition of images obtained from scanning EM (SEM) and NanoSIMS
(Figure 2b). From SEM and transmission EM (TEM), these organelles resemble lamellar bodies (LBs)
based on their size, secretory behavior and morphology, which exhibit more or less packed, occa-
sionally visible lamellae (Figure 2b–c). LBs are lipid-rich secretory organelles specifically produced in
Figure 1 continued
Source data 1. Source files for tumor growth, grades and survival of KP and KPG1 mice.
Figure supplement 1. Non-negative matrix factorization generates four LUAD subtypes, with NMF4 being the closest to KP tumors.
Figure supplement 2. Glut1 is detectable in tumors and the bronchiolar epithelium but not in the alveolar compartment.
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Figure 2. Lamellar body-like organelles are produced by tumor cells and accumulate most glucose-derived biomass. (a) Experimental setting. (b)
Representative examples of a scanning electron microscopy (SEM) images (left), NanoSIMS isotopic image (middle) and their superposition (right)
obtained from a KP tumor. Scale bar: 2 mm. (c) (upper panels) Representative transmission electron microscopy (TEM) images from KP tumors showing
lamellar body-like organelles (LBOs) with different sizes, secretory behavior and presence of lamellae. (lower panels) High-resolution TEM micrographs
showing high magnification lamellae (left), and LBOs with morphologies reminiscent of immature lamellar bodies (LBs) (middle and right). (d) Dot plot
with mean ± s.d. showing the NanoSIMS quantification of 13C-enrichments in LBOs from KP and KPG1 tumors. Each dot represents the measurement of
an individual LBO (n = 239 KP LBOs and n = 325 KPG1 LBOs). ****: p < 0.0001 by Mann-Whitney test. Representative NanoSIMS isotopic images of a
(left) KP and (right) KPG1 tumor cell.
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the lung by AT2 cells, responsible for surfactant production and release into the alveolar space.
Within tumor cells, these LB-like organelles (LBOs) were typically from 200 nm to 2 mm in diameter,
irregularly shaped and darkly stained. Often these contained more heavily stained regions and dis-
cernible tightly packed lamellae at higher magnifications (Figure 2c). Quantitative NanoSIMS images
of these organelles revealed a lower 13C-enrichment signal intensity in KPG1 compared to KP tumor
cells (Figure 2d), demonstrating the consequence of Glut1 loss in vivo.
Despite the differences measured by NanoSIMS, Glut1 deficiency only minimally affected tumor
progression (see Figure 1d–h). We therefore hypothesized the existence of an alternative mecha-
nism that sustains lung tumor growth. First, we isolated KP and KPG1 tumors, prepared single cell
suspensions and tested their glycolytic capacity. In this ex vivo experimental setting, KPG1 tumors
failed to stimulate glycolysis in response to glucose (Figure 3a and Figure 3—figure supplement
1a). As exception, one KPG1 tumor displayed the strongest glycolytic response of all tested tumors,
which coincided with elevated expression of another high-affinity glucose transporter, Glut3
(Figure 3a). To understand better the mechanisms of Glut1-deficient tumor progression, we also
performed RNA sequencing analyses from the non-immune (CD45-) fraction of KP and KPG1 tumors.
To increase the relevance of this comparison, we analysed three cohorts of mice, where tumors were
initiated with Lenti.PGK-Cre, Ad5.SPC-Cre or Ad5.CC10-Cre, the latter two providing SPC+- or
CC10+-cell restricted Cre expression for tumor initiation in distinct cell types (Sutherland et al.,
2014) (see Figure 1—figure supplement 2c). Gene Set Enrichment Analysis (GSEA) highlighted,
from all the Hallmark and KEGG up- and downregulated pathways, a unique significantly shared
pathway between the three cohorts, which was upregulated in KPG1: ‘Hallmark_bile acid metabo-
lism’ (Figure 3—figure supplement 2a). Upon closer examination of the genes included in this path-
way, we identified several target genes of peroxisome proliferator-activated receptor alpha (PPARa)
(Figure 3b), a crucial transcription factor in fatty acid catabolism (Reddy and Hashimoto, 2001).
Furthermore, when interrogating the expression of known PPARa targets (Rakhshandehroo et al.,
2010), GSEA highlighted their enrichment in KPG1 compared to KP tumors (Figure 3c). Thus, KPG1
tumors have a stronger expression of known PPARa-target genes than KP lesions. Together, our
metabolic and molecular analyses suggested two possible and distinct routes for Glut1-deficient
tumor growth: the uptake of the same nutrient through another glucose transporter, Glut3, or via a
PPARa-dependent metabolic shift (Figure 3d).
To test the hypothesis of an involvement of PPARa in lung tumor progression, we cloned a mouse
PPARa-dominant negative construct, PPARaD13 (Michalik et al., 2005), into a bi-promoter Lenti.
Cre vector allowing doxycycline-inducible expression (Lenti.TRE-PPARaD13_PGK-Cre) in KP and
KPG1 tumors (mice were crossed to CCSP-rtTA transgenic mice [Meylan et al., 2009; Figure 3—fig-
ure supplement 3a–b]). Doxycycline-mediated PPARaD13 induction in KP mice led only to a trend
toward a reduction in tumor growth rates, comparable to the growth of KPG1 versus KP tumors.
Within the KPG1 group, PPARaD13 induction did not further reduce tumor growth (Figure 3—figure
supplement 3c). Global gene expression analyses from tumor samples confirmed the functionality of
the PPARaD13 construct in both KP and KPG1 tumors, as ‘Hallmark_bile acid metabolism’, ‘Hall-
mark_fatty acid metabolism’, ‘KEGG_peroxisome’ and ‘KEGG_ fatty acid metabolism’ pathways
were repressed in tumors harboring this construct compared to tumors from KP-rtTA or KPG1-rtTA
mice not fed on a doxycycline diet (Figure 3—figure supplement 3d). Thus, although PPARaD13
downregulates PPARa-related pathways in tumors, it fails to affect their growth even in absence of
Glut1.
To test our second hypothesis, we initially monitored Glut3 expression in tumors. By real-time
PCR, Slc2a3 was expressed to varying levels but not significantly differently between KP and KPG1
tumors (Figure 4—figure supplement 1a). In contrast, Slc2a3 was almost undetectable in tumors
from KrasLSL-G12D; Stk11Flox/Flox (KL) mice (Figure 4—figure supplement 1a), another lung cancer
model where Lkb1 (Stk11)-deficient tumors progressing from an adeno- to a squamous histology
become exquisitely Glut1-dependent (Hsieh et al., 2019). In absence of Glut1 (KLG1), Slc2a3 mRNA
expression remained very low (Figure 4—figure supplement 1a). Accordingly, Glut3 protein was
undetectable by immunohistochemistry in KL and KLG1 tumors, whereas it was expressed in KP and
KPG1 lesions (Figure 4—figure supplement 1b). More specifically, Glut3 stained at the tumor cell
membrane in a minority (37%) of small and a majority (76%) of big KP lesions (Figure 4—figure sup-
plement 1c). Furthermore, within Glut3-expressing KP tumors, areas positive for Glut3 frequently
correlated with a stronger expression of Glut1 (Figure 4a and Figure 4—figure supplement 1d),
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Figure 3. Glut1-deficient tumor analyses suggest Glut3- or PPARa-dependent compensatory mechanisms. (a) (left) Tumor-derived single cell
preparations were placed in a Seahorse XF analyzer and subjected to longitudinal extracellular acidification rate (ECAR) measurements. Glucose or 2-
deoxyglucose (2-DG) were added where indicated. Data are means ± s.e.m. of 3 KP and 3 KPG1 tumor-derived single cells each analyzed in ten or five
technical replicates. The data from the outlier KPG1 are shown separately (orange) from the 2 other KPG1 tumors (red). (right) Real-time PCR and
western blot analyses of Glut1 and Glut3 from the samples analyzed by Seahorse. (b) Bile acid metabolism genes from Hallmark collection (mSigDB)
induced in KPG1 compared to KP from SPC-Cre, CC10-Cre and PGK-Cre tumors. Expression above the median is shown in red, below in green. Genes
in red are PPARa targets (Rakhshandehroo et al., 2010). (c) Gene Set Enrichment Analysis (GSEA) of PPARa targets on genes ranked based on
t-statistics when comparing KPG1 and KP tumors in SPC-Cre, CC10-Cre and PGK-Cre. p-values were obtained by normalized enrichment score (NES) of
105 random permutations. (d) Model illustrating two possible alternatives to Glut1 deficiency for tumor growth.
The online version of this article includes the following source data and figure supplement(s) for figure 3:
Source data 1. Source files for Seahorse analysis of KP and KPG1 tumors.
Figure 3 continued on next page
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suggesting intra-tumor heterogeneity in glucose utilization in this mouse model, as demonstrated
earlier in human non-small cell lung cancer (Hensley et al., 2016). We then crossed KP mice to
Slc2a3Flox/Flox mice (generating KPG3 mice, see Figure 1—figure supplement 2c–d). When compar-
ing tumor development in KP and KPG3 animals, we failed to detect differences in overall tumor
growth rates, ex vivo glycolysis, mouse survival, or tumor grade distribution (Figure 4—figure sup-
plement 2a–d). Although this indicates that Glut3 deletion alone does not affect tumors in a detect-
able manner, we next wanted to evaluate its importance in a Glut1-deficient context. To do this, we
generated KPG1G3 mice by interbreeding KP mice with Slc2a1Flox/Flox and Slc2a3Flox/Flox mice (see
Figure 1—figure supplement 2c–d). Deletion of the two glucose transporters, Glut1 and Glut3,
from the tumor epithelial cell compartment resulted in a decreased number of tumors (Figure 4b).
Furthermore, contrasting with our data obtained from each separately-targeted Gluts, combined
Glut1 and Glut3 deletion led to a significant reduction of tumor growth rates monitored by mCT
scans, to a reduced tumor size with an absence of big (>50 mg) lesions at sacrifice, to a decrease of
high grade tumors, and to an extended mouse survival (Figure 4c–g and Figure 4—figure supple-
ment 3a–b). This synergistic action of the dual Glut1 and Glut3 deletion was also demonstrated in
vitro with four different human NSCLC cell lines, on which the strongest reduction of tumor cell via-
bility resulted from the combined knockdown of these glucose transporters (Figure 4—figure sup-
plement 3c–f). Together, these data position Glut1 and Glut3 as a coordinated glucose transport
unit required to fuel the growth of LUAD.
To trace and compare directly glucose uptake in tumors from the different mouse genotypes, we
used positron emission tomography with 18F-fluorodeoxyglucose (18F-FDG-PET) in KP, KPG1, KPG3,
and KPG1G3 tumors. The maximum standardized uptake value (SUVmax) of each tumor revealed that
Glut1-deficient KP tumors incorporated significantly less 18F-FDG than control lesions (Figure 4h–i),
which strengthens the NanoSIMS data (see Figure 2d). Glut3-deficient and control KP tumors pre-
sented a similar 18F-FDG absorption (Figure 4h–i). This result might be explained by the fact that
Glut3 positive KP tumors mainly co-express Glut1 and Glut3 (see Figure 4—figure supplement 1d).
Thus, in absence of Glut3, lesions might certainly incorporate 18F-FDG via Glut1. The 18F-FDG
absorption of Glut1- and Glut3-deficient KP tumors was significantly reduced as compared to control
KP lesions (Figure 4h–i). Because glucose uptake was not significantly lower in KPG3 compared to
KP tumors, and in KPG1G3 compared to KPG1 tumors, a possible explanation is that most tumors
analyzed had not yet gained Glut3 expression and become dependent on it, which agrees with an
elevated Glut3 expression specifically in big lesions (see Figure 4—figure supplement 1c). Finally,
to investigate if Glut1- and Glut3-deficient tumors might incorporate glucose via another glucose
transporter, we performed a gene expression analysis of glucose transporter family members on KP
and KPG1G3 lesions. This analysis showed that the expression of no other glucose transporter was
changed upon dual Glut1 and Glut3 deletion in KP tumors (Figure 4—figure supplement 4a). Alto-
gether, these data demonstrate that deleting Glut1 and Glut3 in KP tumors reduces glucose uptake,
and that Glut1 highly contributes to glucose uptake in KP tumors. These results may also lead to the
hypothesis that at least a part of the remaining 18F-FDG-PET signal detected in KPG1G3 tumors
might come from glucose uptake by the cells of the tumor immune microenvironment.
Recently, pharmacological inhibition of a secondary active, Na+-dependent glucose transporter,
Sglt2, showed its role in premalignant KP lung lesions (Scafoglio et al., 2018), while a glycolytic
switch was identified in advanced compared to early tumors (Kerr et al., 2016). These studies,
together with our gene targeting approaches, definitively demonstrate the importance of glucose
utilization for LUAD development in vivo. In the KL model, Glut1 deletion impairs LUSC develop-
ment (Hsieh et al., 2019), and we find that Lkb1-deficient lung tumors lack detectable Glut3, pre-
cluding any compensation occurring through this transporter. In contrast, in pure LUAD our results
Figure 3 continued
Figure supplement 1. Glut1 deletion compromises ex vivo glycolytic metabolism.
Figure supplement 1—source data 1. Source files for Seahorse analysis of KP and KPG1 tumors.
Figure supplement 2. Hallmark ‘bile acid metabolism’ is upregulated in Glut1-deficient tumors.
Figure supplement 3. PPARaD13 does not interfere with tumor development of KP and KPG1 mice.
Figure supplement 3—source data 1. Source files for tumor growth of KP and KPG1 mice, with or without PPARaD13 induction.
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Figure 4. Combined Glut1 and Glut3 deletion impairs lung tumor growth. (a) Representative examples of H&E, Glut1 or Glut3 staining by IHC from
serial sections of a KP tumor showing Glut1-3 co-localization. Scale bars: 200 mm. (b) Histogram with mean ± s.d. shows the average number of KP and
KPG1G3 tumors per mouse (n = 4 and 6 mice). *: p < 0.05 by Mann-Whitney test. (c) Graph with mean ± s.e.m. shows the fold changes of KP and
KPG1G3 tumor volumes (n = 8 and 9 tumors) monitored during 43 days by mCT, starting at 15 weeks and 2 days post-tumor initiation with tumor
Figure 4 continued on next page
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indicate that Trp53-deficient tumor cells depend on glucose uptake based on a redundant system,
whereby the expression of either Glut1 or Glut3 is sufficient to sustain tumor growth (Figure 4j). For
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Figure 4 continued
volumes set to 1. ns: not significant by Mann-Whitney test; *: p < 0.05 by Mann-Whitney test. (d) Dot plot with mean ± s.d. shows tumor areas in KP and
KPG1G3 mice (n = 115 and 101 tumors) calculated from lung sections. **: p < 0.01 by Mann-Whitney test. (e) Dot plot with mean ± s.d. shows KP and
KPG1G3 tumor weights (n = 8 and 9 tumors, respectively) at sacrifice. **: p < 0.01 by Mann-Whitney test. (f) Percent of KP (n = 150) and KPG1G3 (n =
170) lesions classified by tumor grades, either detailed from alveolar hyperplasia (AH) to grade 5 or discriminated between alveolar hyperplasia and
adenomas, and adenocarcinomas. Alveolar hyperplasia and adenomas include the AH and the tumor grades 1, 2, and 3. Adenocarcinomas contain the
tumor grades 4 and 5. *: p < 0.05; **: p < 0.01. Fisher test was applied when comparing AH, grade 1, grade 2, grade 3, grade 4, and grade 5. Chi-
square for trend was applied when comparing alveolar hyperplasia and adenomas, and adenocarcinomas. (g) Kaplan-Meier survival analysis of KP (n =
8) and KPG1G3 (n = 6) mice. *: p < 0.05 by Log-rank test. (h) Representative (upper panels) positron emission tomography (PET) scan and (lower panels)
mCT scan images illustrating the 18F-FDG absorption of KP, KPG1, KPG3 and KPG1G3 tumors. (i) Dot plot with mean ± s.d. displays maximum
standardized uptake value (SUV max ) of KP (n = 17), KPG1 (n = 24), KPG3 (n = 32) and KPG1G3 (n = 38) lesions. ns: not significant by Mann-Whitney
test; ****: p < 0.0001 by Mann-Whitney test. (j) Model illustrating the dependency on glucose transporters for KP and KL tumor progression.
The online version of this article includes the following source data and figure supplement(s) for figure 4:
Source data 1. Source files for tumor growth, grades and survival of KP and KPG1G3 mice.
Figure supplement 1. Glut1 and Glut3 co-localize frequently within tumors.
Figure supplement 2. Glut3 deletion alone does not affect lung tumor development.
Figure supplement 2—source data 1. Source files for tumor growth, Seahorse analysis, survival and grades of KP and KPG3.
Figure supplement 3. Dual knockdown of GLUT1 and GLUT3 most strongly reduces human non-small cell lung cancer cell viability in vitro,
corroborating the in vivo data.
Figure supplement 3—source data 1. Source files for tumor growth of KP and KPG1G3 mice.
Figure supplement 4. KP tumors do not express differently another glucose transporter upon dual Glut1 and Glut3 deletion.
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The Cancer Genome Atlas (TCGA) Lung Adenocarcinoma (LUAD) dataset was retrieved from http://
cancergenome.nih.gov. Samples with clinical information and mRNA (RNASEQV2) expression data
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were selected (511 samples including 448 samples with survival data), and the data were down-
loaded using the RTCGAtoolbox (v2.12.1). RSEM gene quantifications as provided by TCGA were
taken, counts were converted to log2 normalized counts expression and batch effect was removed
using voom and removeBatchEffect functions from the limma package (v3.38.3).
Non-negative matrix factorization
Non-negative matrix factorization (NMF) was done with the NMF package (v0.21.0) and standard
strategies applied to the matrix in 511 normalized TCGA-LUAD samples. Negative values present in
the dataset were zeroed to obtain a non-negative matrix, and the NMF was performed for ranks 2
to 6 using the Brunet algorithm. Two hundred runs were performed per rank with random seeding.
For each rank, the cophenetic correlation coefficient and silhouette score were computed from the
200 solutions and the factorization achieving the minimum residual error was kept as the solution for
further analyses. The cophenetic correlation coefficients and silhouette scores were directly obtained
using the plot function of the NMF package. As a control, the NMF was also performed on a ran-
domized dataset built by taking within each patient a random permutation of the gene expression
values, using the randomize function of the NMF package. After having selected rank four as the
best one, the NMF was rerun only for rank four and for a superior number of runs (500 runs). The
final NMF-based matrix is composed of 935 metagenes and 511 samples split into four subtypes
(shown as a heatmap). Correspondence to the three subtypes found by the Cancer Genome Atlas
Research Network (The Cancer Genome Atlas Research Network, 2014) (proximal proliferative,
proximal inflammatory and terminal respiratory unit) and presence of TP53 mutation are shown on
top bars.
To identify which human NMF subtype corresponds the most to KP mouse bulk Lenti tumors, we
combined mouse and human normalized expression data, removed batch effect using ComBat
(package sva v3.30.1), fitted a logistic regression to the human data set using glmnet package (v2.0–
18) and 10-fold cross-validation with default parameters, and applied the fitted model as prediction
method to the mouse data. Human and mouse orthologous genes were obtained using biomaRt
(v2.38.0) and only genes in common between mouse and human were used.
Human survival analysis
Univariate analyses of overall survival (OS) were performed using Cox proportional hazard regression
models available in the survival package (v2.44–1.1). Survival curves were computed with the Kaplan-
Meier method. p-values were computed with Wald test.
Study approval
All mouse experiments were performed with the permission of the Veterinary Authority of Canton
de Vaud, Switzerland (license numbers: VD2391 and VD2663).
Animal models
KrasLSL-G12D/WT (K) (RRID:IMSR_JAX:008179) and Trp53Flox/Flox mice (P) (RRID:IMSR_JAX:008462) in a
C57BL6/J background were purchased from The Jackson Laboratory, and were crossed to obtain
KrasLSL-G12D/WT; Trp53Flox/Flox (KP) mice. Stk11Flox/Flox mice in a mixed background (FVB; 129S6) were
obtained from R. DePinho (The University of Texas MD Anderson Cancer Center) through the
National Cancer Institute mouse repository, were backcrossed seven times to C57BL6/J and were
bred with KrasLSL-G12D/WT mice to obtain KrasLSL-G12D/WT; Stk11Flox/Flox (KL) mice. The generation of
the Slc2a1Flox/Flox (G1) mice and Slc2a1 genotyping were described previously (Young et al., 2011).
Slc2a3Flox/Flox (G3) mice were produced at the Duke University Transgenic Facility upon blastocyst
microinjection of targeted ES cells obtained from KOMP Repository (project CSD48048). The result-
ing mice were then crossed to Flp transgenic mice to remove the neomycin resistance cassette and
generate mice with a Slc2a3Flox allele, in which exon six is flanked by LoxP sites. Slc2a3 genotyping
was performed by PCR (94˚C 5 min, followed by 40 cycles of 94˚C 30 s, 56˚C 30 s and 72˚C 30 s, fol-
lowed by 72˚C 7 min) using oligos 5’-TAGTGCCCAGGAATGTGAGGTCAG-3’ and 5’-GCCCCAC-
CAGATTTACCAAAGG-3’. While heterozygous mice were identified this way, in cases with only one
detected band, DNA sequencing was further performed to discriminate without ambiguity between
wild-type and floxed using 5’-TAGTGCCCAGGAATGTGAGGTCAG-3’.
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KP mice were bred to G1 or G3 to obtain KPG1, KPG3 or KPG1G3 mice. KL mice were bred to
G1 to obtain KLG1 mice. Control mice used throughout the study carry two wild-type (WT) copies of
Slc2a1 (or Slc2a3) or are heterozygotes (Slc2a1WT/Flox), as we did not notice any difference of tumor
development comparing Slc2a1WT/WT to Slc2a1WT/Flox conditions. CCSP-rtTA mice were obtained
from The Jackson Laboratory and were crossed to KP and KPG1 mice to enable doxycycline-medi-
ated PPARaD13 transgene expression. For transgene induction, mice were fed on a diet of doxycy-
cline-containing pellets (625 mg kg 1; 3242 diet + DOX 0.625 g kg 1; Kliba Nafag) for 15 days, or
on a regular diet as control.
Viral constructs
The dominant-negative mouse PPARa construct, PPARaD13 (Michalik et al., 2005), was cloned into
bi-promoter Lenti.Cre vectors for doxycycline-inducible expression (Lenti.TRE-PPARaD13_PGK-Cre).
Lentivirus preparation and titration have been described before (Faget et al., 2017). Lenti.TRE-
PPARaD13_PGK-Cre vectors were intratracheally instilled at 6000 lentiviral units per mouse. Lenti.
PGK-Cre vectors were used either at 3000 lentiviral units per mouse or at 4000 lentiviral units per
mouse. Adenoviral vectors Ad5.SPC-Cre and Ad5.CC10-Cre were purchased from the University of
Iowa Viral Vector Core Facility and used for intratracheal instillation at 2.108 PFU per mouse.
Tumor volume measurements
Longitudinal tumor volume monitoring was performed by X-rays micro-computed tomography (mCT;
Quantum FX; PerkinElmer). Mice were anaesthetized using isoflurane (Piramal, 56.761.002) before
the scanning procedure. Animals were then maintained under anesthesia during lung imaging set at
50 mm voxel size, with retrospective gating. Individual tumor volumes were measured and calculated
either with Analyze 12.0 software (PerkinElmer) or with OsiriX MD software (Pixmeo; RRID:SCR_
013618).
Mouse survival analysis
Overall mouse survival was evaluated considering actual mouse death or when lung tumor burden
compelled to sacrifice. Control KP mice were the same for the three Kaplan-Meier analyses
performed.
Assessment of tumor parameters
Tumor grading was assessed from haematoxylin and eosin (H and E) stained lung sections by an
experienced veterinary pathologist (CG), based on a previous classification system (Jackson et al.,
2005). Briefly, lesions were categorized as alveolar hyperplasia (AH), or as tumor on a 1–5 severity
grading scale from grade one adenomas to grade five adenocarcinomas. Glut1 staining (defined as
weak, intermediate or strong) was monitored in all grades. Tumor numbers were counted from lung
sections. Tumor areas were calculated from lung sections using QuPath (Bankhead et al., 2017;
RRID:SCR_018257). To evaluate Glut3 staining, tumors were categorized into small or big lesions
based on their diameter on histology sections (small <0.82 mm< big); this diameter was chosen
because it was the median diameter of all tumors from a test KP cohort. To determine tumor
weights, the biggest visible tumors per mouse at autopsy were macro-dissected and immediately
weighed. To determine Glut1-3 correlation, KP tumor-bearing lung serial sections stained for Glut1
or Glut3 were analyzed.
Preparation of lung tumors for electron microscopy (TEM and SEM) and
NanoSIMS
Tumor-bearing KP and KPG1 mice at 21 weeks post-tumor initiation were injected intraperitoneally
with a solution containing 13C-glucose (or 12C-glucose as control), four times every 45 min, begin-
ning 3 hr prior to sacrifice, for a total of 7.5 g kg 1. Mice were then perfused via the heart with a
buffered mix of 1.0% glutaraldehyde and 2.0% paraformaldehyde in 0.1 M phosphate buffer (pH
7.4). After 2 hr, the lungs were removed and placed in the same fixative overnight. They were then
sectioned with a vibratome (VT1200, Leica Microsystems) at a thickness of 100 mm, and the sections
of interest, showing distinct tumors, washed thoroughly with cacodylate buffer (0.1 M, pH 7.4).
These were then postfixed for 40 min in 1.0% osmium tetroxide with 1.5% potassium ferrocyanide in
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cacodylate buffer, and then 40 min in 1.0% osmium tetroxide alone (in cacodylate buffer). They were
finally stained for 30 min in 1% uranyl acetate in H2O before being dehydrated through increasing
concentrations of EtOH and then embedded in Durcupan ACM (EMS, USA) resin. The resin-embed-
ded sections were hardened for 24 hr in an oven at 65˚C. Regions of interest were sectioned either
at 50 nm thickness, and collected on single slot grids, for transmission electron microscopy (TEM), or
at 0.5 mm thickness, and collected on silicon wafers, for scanning electron microscopy (SEM) and
NanoSIMS analysis. Sections collected on grids were further contrasted with lead citrate and uranyl
acetate solutions, and images taken using a transmission electron microscope (Spirit TEM, operating
at 80 kV, FEI Company) with digital camera (Eagle CCD camera; FEI Company). SEM imaging of sec-
tions on silicon wafers for correlation with NanoSIMS images was performed using a Zeiss Gemini-
SEM 500. Imaging was done at 3 kV, using an energy selective backscatter detector (EsB) with a grid
bias of 1500 V. NanoSIMS images of cells selected from SEM images were acquired using a Cs+ pri-
mary beam. Selected areas (usually 50  50 mm for entire cell images or 25  25 mm for specific
areas within a cell) were first implanted in order to clean up the surface and reach stable emission
conditions. The areas were then imaged by scanning the Cs+-beam focused on the surface of the
sample; beam diameter was about 200 mm and current 1.8 pA for the 50  50 mm images and about
100 mm with a current of 0.5 pA for the 25  25 mm images. Number of pixels were always 256 
256 and dwell time 5 ms/pixel. For each image, eight layers were acquired and processed using Loo-
katNanosims software (Polerecky et al., 2012). The layers were aligned and stacked. Using a SEM
image aligned with the NanoSIMS images, areas of interests were drawn for every LBO.
Protein extraction for western blot
For transient transfection, 293 T cells were co-transfected with an rtTA plasmid and the Lenti.TRE-
PPARaD13_PGK-Cre construct using LF2000 (ThermoFisher Scientific), and were treated (or not)
with 2 mg ml 1 doxycycline one day later for 24 hr to monitor PPARaD13 induction. For all experi-
ments, cells were lysed in RIPA (150 mM NaCl, 20 mM Tris pH 7.4, 0.1% SDS, 0.5% NP-40, 0.5%
sodium deoxycholate, 1 mM sodium orthovanadate, one protease inhibitor cocktail tablet
(11836145001, Roche)). Proteins were quantified using a BCA assay, and 50 mg (or 5 mg after Sea-
horse) was used for western blot. Antibodies used are anti-PPARa (PA1-822A, ThermoFisher Scien-
tific, 1:1000; RRID:AB_2165595), anti-GLUT1 (07–1401, Millipore, 1:1000; RRID:AB_1587074), anti-
GLUT3 (ab41525, Abcam, 1:1000; RRID:AB_732609), anti-b-tubulin (sc-9104, Santa Cruz Biotechnol-
ogy, 1:1000; RRID:AB_2241191), and anti-g-tubulin (T6557, Sigma-Aldrich, 1:10’000; RRID:AB_
477584).
Immunohistochemistry on mouse tissues
For histological analyses, lung lobes from tumor-bearing mice were fixed in 3,6% formaldehyde
(VWR Chemicals, 20909.290) at 4˚C for 24 hr, then rinsed once in PBS1x followed by a washing and
a keeping in 70% absolute ethanol (VWR, C20820.362) before paraffin embedding. Lung paraffin
blocks were sectioned at 4 mm using a rotary microtome (Thermo Scientific, HM325), mounted on
slides, dried at 37˚C overnight before being stored at 4˚C. Lung tissue sections were dewaxed, fol-
lowed by antigen retrieval in a 10 mM Trisodium Citrate buffer pH 6.0 for 20 min at 95˚C. Slides
were then washed three times for 5 min in PBS1x before endogenous peroxidase blockade with
0.3% hydrogen peroxide (VWR, 1.07209.0250) for 10 min at room temperature (RT). Next, lung sec-
tions were washed three times for 5 min in PBS1x + 0.2% Triton X-100 (Sigma Aldrich, 93420), and
blocked in 5% goat serum in PBS1x + 0.2% Triton X-100 for 1 hr at RT. Mouse tissue sections were
stained with anti-GLUT1 (ab115730, Abcam, 1:650; RRID:AB_10903230) or anti-GLUT3 (ab41525,
Abcam, 1:200; RRID:AB_732609) antibodies in blocking solution, 5% goat serum in PBS1x + 0.2%
Triton X-100, overnight at 4˚C. The day after, slides were incubated 30 min at RT, and washed three
times for 5 min in PBS1x + 0.2% Triton X-100. Tissue sections were incubated 1 hr in biotin-conju-
gated secondary antibodies in blocking solution, 5% goat serum in PBS1x + 0.2% Triton X-100. Sec-
tions were then washed three times for 5 min in PBS1x + 0.2% Triton X-100, incubated for 30 min in
avidin-biotin HRP complexes (Vector Laboratories, Vectastain Elite ABC HRP kit, PK-6105), and
revealed with a 3,3’-diaminobenzidine (DAB) peroxidase substrate kit (Vector Laboratories, SK-
4100). Harris haematoxylin counterstains were performed. Sections immunohistochemically stained
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were imaged with a Leica microscope (Olympus BX43/U-HGLGPS), or scanned using a slide scanner
(Olympus, VS120-L100).
Human microarray and immunohistochemistry
A tissue microarray (TMA) comprising 36 randomly selected human non-small cell lung cancers (18
stage IB-IIB LUAD, 18 stage IA-IIB LUSC based on the 7th Edition of the UICC TNM classification)
was generated by SB using the Translational Research Unit Platform of the Institute of Pathology,
University of Bern, as described previously (Zlobec et al., 2013). Tumors were resected between
1990 and 2007. Representative H&E slides from all cases were scanned using a digital slide scanner
(Pannoramic P250, Budapest, Hungary). Using a digital TMA annotation tool, each scan was marked
using eight cores per tumor of 0.6 mm diameter each. Annotated images were aligned with the
tumor block and cored out automatically (TMA Grand Master, 3DHistech, Hungary), producing a
next-generation Tissue Microarray (ngTMA). The ngTMA block was cut at 4 mm and a double IHC
using anti-GLUT1 (AEC chromogen, red staining) and anti-HIF1a (DAB chromogen, brown staining)
was performed. Data on HIF1a were not considered in this study. Anti-GLUT1 (07–1401, Millipore,
1:5000; RRID:AB_1587074) was incubated for 30 min. Antigen retrieval was done in citrate buffer for
30 min at 100˚C. GLUT1 membrane staining on tumor cells was classified by an experienced patholo-
gist (CN) into score 0 (no or weak staining in tumor cells in all eight cores), score 1 (intermediate
staining in tumor cells in at least 1 of the eight cores) or score 2 (strong staining in tumor cells in at
least 1 of the eight cores). No score 0 was present. Visual scoring was done using Scorenado, an
automated core-wise digital image display and documentation tool based on QuPath elements
(Lytle et al., 2019).
RNA isolation, reverse transcription and real-time PCR
Single cell suspensions from macro-dissected tumors were obtained using a gentleMACS Octo Dis-
sociator (Miltenyi Biotec). RNA was prepared for sequencing from bulk tumors (bulk Lenti) or from
CD45- (non-immune) tumor fractions (PGK-Cre, SPC-Cre and CC10-Cre). In the latter case, magnetic
cell sorting to remove immune cells was performed using anti-CD45 MicroBeads (130-052-301, Mil-
tenyi Biotec). RNA for real-time PCR or sequencing was extracted using TRIzol (15596018, Thermo-
Fisher Scientific). For real-time PCR, 1 mg RNA was used for reverse transcription using High-
Capacity cDNA Reverse Transcription Kit (4368814, ThermoFisher Scientific). Real-time PCR was
done using Taqman universal PCR master mix (4324018, ThermoFisher Scientific) and Taqman
probes for the following genes: Slc2a1: Mm00441480_m1; Slc2a3: Mm00441483_m1; Slc2a2:
Mm00446229_m1; Slc2a4: Mm00436615_m1; Slc2a5: Mm00600311_m1; Slc2a6: Mm00554217_m1;
Slc2a7: Mm01260610_m1; Slc2a8: Mm00444634_m1; Slc2a9: Mm00455122_m1; Slc2a10:
Mm01249519_m1; Slc2a12: Mm02375931_s1; Slc2a13: Mm01306489_m1; Slc5a2:
Mm00453831_m1; Slc50a1: Mm00485707_m1; gene expression level normalization gene Rpl30:
Mm01611464_g1 (all from ThermoFisher Scientific, Catalog number: 4331182). Data were presented
as DCT values.
Mouse mRNA sequencing, differential expression, and pathway
analyses
Multiplexed libraries for mRNA-seq were prepared with the TruSeq stranded mRNA kit (Illumina)
starting from 500 ng of good-quality total RNAs (RNA quality scores > 7 on the Fragment Analyzer).
Sequencing was subsequently performed on a NextSeq 500 instrument (Illumina) on a high-output
flow cell, yielding single-end reads of 85 nucleotides. Adapter sequences and low-quality ends were
removed with Cutadapt (v1.9.1), trimming for TrueSeq and polyA sequences. Reads were aligned to
mouse genome build mm10 using HISAT2 aligner (v2.0.3beta). Genes with low expression were fil-
tered out (average transcripts per kilobase million < 20). Counts were normalized for library size
using TMM method from EdgeR (v3.24.3) and voom from limma. Differential expression was com-
puted with limma between Glut1-KO and WT control, or PPARaD13 and control.
We investigated pathways as defined in the Hallmark and KEGG collections of MSigDB (v6.0;
Subramanian et al., 2005). Gene Set Enrichment Analysis (GSEA) was performed on genes ranked
based on t-statistics obtained when comparing Glut1-KO and WT control, or PPARaD13 and control.
Statistical significance was calculated by permutation tests (number of random permutations = 105).
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Seahorse analyses
Single cell suspensions were prepared from macro-dissected tumors using gentleMACS Octo Disso-
ciator (Miltenyi Biotec). Macro-dissected tumors were weighted and processed into DMEM, no glu-
cose (11966025, ThermoFisher Scientific). Ten or five technical replicates per tumor (5 mg of tumor
per replicate) were plated in a XF96 V3-PS cell culture microplate (Seahorse Bioscience, North Biller-
ica) and the rest of cell suspensions were saved for real-time PCR. Cells were incubated during 2 hr
in DMEM, no glucose at 37˚C. Extracellular acidification rates (ECAR) were then measured using
XFe96 Extracellular Flux Analyzer (Seahorse Bioscience, North Billerica, MA). ECAR measurements
were performed at 37˚C, with measurement cycles broken down into 2 min of mixing, 2 min of wait-
ing and 3 min of data acquisition. During Seahorse assay, 10 mM of glucose was added, followed by
50 mM of 2-deoxyglucose (2-DG). ECAR measurements were reported as normalized to protein con-
centration. After Seahorse analysis, proteins were extracted from the cells for western blot analyses.
Cell line authentication
Cell line authentication was performed by Microsynth AG. Profiling of the human cell lines was done
using highly polymorphic short tandem repeat loci (STRs). STR loci were amplified using the Power-
Plex 16 HS System (Promega). Fragment analysis was done on an ABI3730xl (Life Technologies) and
the resulting data were analyzed with GeneMarker HID software (Softgenetics). A549, Calu-6, and
H460 cell lines matched 100% to the DNA profile of A549 (ATCC CRM-CCL-185TM; RRID:CVCL_
0023), Calu-6 (ATCC HTB-56TM; RRID:CVCL_0236), and NCI-H460 [H460] (ATCC HTB-177TM; RRID:
CVCL_0459), respectively. SW 1573 cell line matched 93,3% to the DNA profile of the SW 1573 [SW-
1573, SW1573] (ATCC CRL-2170TM; RRID:CVCL_1720).
Mycoplasma test on human cell lines
Mycoplasma test (13100–01, Mycoplasma Detection Kit, SouthernBiotech) was performed on the 4
cell lines used for the in vitro experiments. All cell lines were mycoplasma negative.
In vitro human non-small cell lung cancer experiments
Mycoplasma negative and authenticated human Calu-6, H460, A549 and SW 1573 cell lines were
plated in 6-well culture plates in RPMI (Gibco, 21875–034) supplemented with 10% FBS (Gibco,
10270106) at 1.105 cells per well. One day later, cells were transfected using lipofectamine RNAi
max (Life Technologies, 13778150) with siRNAs: siCTR, siSLC2A1, siSLC2A3, or siSLC2A1 +
siSLC2A3. References and mixes of the siRNAs used for the different conditions are found in Table 1.
72 hr after transfection, cells were counted using Trypan blue dye exclusion assay (Invitrogen,
T10282) and an automated cell counter (Invitrogen, Countess Automated Cell Counter). Cells were
then lysed into TRIzol (Invitrogen, 15596018) to extract RNA.
18F-fluorodeoxyglucose with positron emission tomography (18F-FDG
PET)
In vivo measurements of the tumors’ glucose uptake were performed on a group of animals (n = 14,
i.e. 3 KP, 4 KPG1, 3 KPG3 and 4 KPG1G3, fasted overnight) with positron emission tomography
(PET) as previously described in detail (Lanz et al., 2014). Mice were anesthetized with a mixture of
4% isoflurane (vol/vol) in 100% O2 for 2 min and then maintained with a mixture of 1.5% isoflurane in
100% O2 (0.9 L/min) during tail catheter insertion and initial glycaemia measurement. PET data were
acquired on an avalanche photodiode–based LabPET-4 small-animal scanner (Gamma Medica, Sher-
brook, Canada). Mice were prone positioned on a heat-regulated scanner bed with respiratory cush-
ion and rectal temperature measurement probe, with the PET scanner field of view adjusted to
cover the chest area. A bolus injection of 18F-fluorodeoxyglucose (18F-FDG) (~20 MBq) was adminis-
tered through the tail vein catheter within the first 30 s of the PET scan, followed by 150–200 ml of
saline chase solution. During the 60 min scan, mice were maintained under 1.5–2% (vol/vol) isoflur-
ane anesthesia in oxygen (0.9 L/min). Monitored temperature and breathing rate were maintained
within a physiological range. Raw data were reconstructed with a maximum likelihood expectation
maximization (MLEM) algorithm on a circular FOV of 60 mm of diameter and a standard voxel size of
0.50.51.18 mm, in three time frames of 20 min. The last time frame (labeling steady-state) was used
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to derive standardized uptake values (SUV) images and measure maximal SUV (SUVmax) values over
tumor regions.
SUV g=ml½  ¼
RROI kBq=ml½ 
Ainj kBq½ =w g½ 
where RROI represents the radioactivity concentration measured in the region of interest (ROI), Ainj is
the injected activity corrected for the radiotracer decay and w is the mouse weight.
PMOD 2.95 software (PMOD Technologies, Zurich) was used for the determination of the stan-
dardized uptake value (SUV) and for the delineation of the tumors’ ROIs, based on a visual slice-by-
slice matching with the corresponding mCT images. Tumors appearing on consecutive slices were
grouped as single VOIs for the calculation of the SUVmax.
Statistical analyses and graphic design
Statistical analyses were performed, and graphics produced using R version 3.5.1, Prism version
eight or Microsoft Excel version 16.
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Table 1. References of the siRNAs used for in vitro experiments.
siRNA Mixes of Species Supplier References
siCTR siCTR Human and Mouse Invitrogen Cat# 4390843
siSLC2A1 siSLC2A1#1 Human ThermoFisher Scientific s12926
Cat# 4390824
siSLC2A1#2 Human ThermoFisher Scientific s12927
Cat# 4390824
siCTR Human and Mouse Invitrogen 4390843
siSLC2A3 siSLC2A3#1 Human ThermoFisher Scientific s12931
Cat# 4390824
siSLC2A3#2 Human ThermoFisher Scientific s12932
Cat# 4390824
siCTR Human and Mouse Invitrogen Cat# 4390843
siSLC2A1
+ siSLC2A3
siSLC2A1#1 Human ThermoFisher Scientific s12926
Cat# 4390824
siSLC2A1#2 Human ThermoFisher Scientific s12927
Cat# 4390824
siSLC2A3#1 Human ThermoFisher Scientific s12931
Cat# 4390824
siSLC2A3#2 Human ThermoFisher Scientific s12932
Cat# 4390824
Contat et al. eLife 2020;9:e53618. DOI: https://doi.org/10.7554/eLife.53618 17 of 21
Short report Cancer Biology
Additional information
Funding
Funder Grant reference number Author








Swiss National Science Foun-
dation
PP00P3_133661 Etienne Meylan




Anna Fuller Fund Caroline Contat
Etienne Meylan




The funders had no role in study design, data collection and interpretation, or the
decision to submit the work for publication.
Author contributions
Caroline Contat, Conceptualization, Formal analysis, Supervision, Validation, Investigation, Visualiza-
tion, Methodology, Project administration; Pierre-Benoit Ancey, Formal analysis, Validation, Investi-
gation, Visualization, Project administration; Nadine Zangger, Software, Formal analysis, Validation,
Investigation, Visualization; Silvia Sabatino, Justine Pascual, Louise Jensen, Anouk Rossier, Stéphanie
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